December 8 (China News) -- At the press conference held by the State Food and Drug Administration today, spokesperson Yan Jiangying clearly stated that the four death cases following inoculation of the A/H1N1 flu vaccine had no direct connection with the vaccine. Yan Jiangying said that so far, most people who were vaccinated after National Day holidays have developed fever or cold to different degrees, which are the same adverse reactions as those of seasonal influenza vaccines, and no serious adverse reaction has been found yet following inoculation of the A/H1N1 flu vaccine. It can be said that the A/H1N1 flu vaccine now on the market is safe and effective. Yan Jiangying emphasized that the A/H1N1 flu vaccine has gone through strict clinical trials and strict examination and approval by pharmaceuticals regulatory departments. In the process of vaccine development, pharmaceuticals regulatory departments carried out strict examination for enterprises already approved to produce medicines, conducted strict supervision in the production process, and performed lot release before marketing. Finally, Yan Jiangying said that although the review and approval of the A/H1N1 flu vaccine was completed within a short period of time, many works were carried out in an overlapping manner within a short time, without lowering any standard or reducing any procedure.